Copyright © 2003 by the European Society of Cardiology.
Regular Articles
The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol
Hospital of the Westfälische Wilhelms-University, Department of Cardiology and Angiology, Institute for Arteriosclerosis Research, Münster, Germany
* Corresponding author: Sascha Rolf, MD, Universitätsklinikum Münster, Medizinische Klinik und Poliklinik C, Kardiologie und Angiologie, Albert-Schweitzer-Str. 33, D-48145 Münster, Germany. Tel.: +49-251-8347580; fax: +49-251-8348640
E-mail address: srolf{at}uni-muenster.de
Received 17 December 2002; revised 17 February 2003; accepted 26 February 2003
Aims The diagnostic ECG pattern in Brugada syndrome (BS) can transiently normalize and may be unmasked by sodium channel blockers such as ajmaline. Proarrhythmic effects of the drug have been well documented in the literature. A detailed protocol for the ajmaline challenge in Brugada syndrome has not yet been described. Therefore, we prospectively studied the risks of a standardized ajmaline test.
Methods and results During a period of 60 months, 158 patients underwent the ajmaline test in our institution. Ajmaline was given intravenously in fractions (10mg every two minutes) up to a target dose of 1mg/kg. In 37 patients (23%) the typical coved-type ECG pattern of BS was unmasked. During the test, symptomatic VT appeared in 2 patients (1.3%). In all other patients, the drug challenge did not induce VT if the target dose, QRS prolongation >30%, presence/appearance of the typical ECG, or the occurrence of premature ventricular ectopy were considered as end points of the test. A positive response to ajmaline was induced in 2 of 94 patients (2%) with a normal baseline ECG, who underwent evaluation solely for syncope of unknown origin.
Conclusion The ajmaline challenge using a protocol with fractionated drug administration is a safe method to diagnose BS. Because of the potential induction of VT, it should be performed under continuous medical surveillance with advanced life-support facilities. Due to the prognostic importance all patients with aborted sudden death orunexplained syncope without demonstrable structural heart disease and family members of affected individuals should presently undergo drug testing for unmasking BS.
Key Words: Brugada syndrome • Ajmaline challenge • Test protocol • Proarrhythmia • Safety
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- The ajmaline challenge in Brugada syndrome: A useful tool or misleading information?
- J Brugada, P Brugada, and R Brugada
EHJ 2003 24: 1085-1086.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  R. Surber, S. Hensellek, D. Prochnau, G. S. Werner, K. Benndorf, H. R. Figulla, and T. Zimmer Combination of cardiac conduction disease and long QT syndrome caused by mutation T1620K in the cardiac sodium channel Cardiovasc Res, March 1, 2008; 77(4): 740 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Peters Arrhythmogenic right ventricular dysplasia-cardiomyopathy and provocable coved-type ST-segment elevation in right precordial leads: clues from long-term follow-up Europace, February 27, 2008; (2008) eun030v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Paul, J. Gerss, E. Schulze-Bahr, T. Wichter, C. Vahlhaus, A. A.M. Wilde, G. Breithardt, and L. Eckardt Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data Eur. Heart J., September 1, 2007; 28(17): 2126 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Keller, H. Huang, J. Zhao, R. Frank, V. Suarez, E. Delacretaz, M. Brink, S. Osswald, N. Schwick, and M. Chahine A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation Cardiovasc Res, June 1, 2006; 70(3): 521 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Meregalli, A. A.M. Wilde, and H. L. Tan Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res, August 15, 2005; 67(3): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antzelevitch, P. Brugada, M. Borggrefe, J. Brugada, R. Brugada, D. Corrado, I. Gussak, H. LeMarec, K. Nademanee, A. R. Perez Riera, et al. Brugada Syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association Circulation, February 8, 2005; 111(5): 659 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kies, T. Wichter, M. Schafers, M. Paul, K. P. Schafers, L. Eckardt, L. Stegger, E. Schulze-Bahr, O. Rimoldi, G. Breithardt, et al. Abnormal Myocardial Presynaptic Norepinephrine Recycling in Patients With Brugada Syndrome Circulation, November 9, 2004; 110(19): 3017 - 3022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hong, J. Brugada, A. Oliva, A. Berruezo-Sanchez, D. Potenza, G. D. Pollevick, A. Guerchicoff, K. Matsuo, E. Burashnikov, R. Dumaine, et al. Value of Electrocardiographic Parameters and Ajmaline Test in the Diagnosis of Brugada Syndrome Caused by SCN5A Mutations Circulation, November 9, 2004; 110(19): 3023 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bordachar, S. Reuter, S. Garrigue, X. Cai, M. Hocini, P. Jais, M. Haissaguerre, and J. Clementy Incidence, clinical implications and prognosis of atrial arrhythmias in brugada syndrome Eur. Heart J., May 2, 2004; 25(10): 879 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Brugada, P Brugada, and R Brugada The ajmaline challenge in Brugada syndrome: A useful tool or misleading information? Eur. Heart J., June 2, 2003; 24(12): 1085 - 1086. [Full Text] [PDF]
|
|